Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.71 |
| ▸ | RXRA | P19793 | 6/20 | 0.60 |
| ▸ | RXRB | P28702 | 6/20 | 0.60 |
| ▸ | RXRG | P48443 | 5/20 | 0.60 |
| ▸ | ESR1 | P03372 | 4/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.52 |
| ▸ | BCR | P11274 | 2/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.45 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28217088 | 0.86 | KIF11 (0.59) | KIF11RXRARXRBRXRGESR1 | |
| SCHEMBL12675678 | 0.83 | KIF11 (1.00) | KIF11ESR1ESR2DGAT1KCNH2 | |
| SCHEMBL678508 | 0.83 | KIF11 (1.00) | KIF11ESR1ESR2DGAT1KCNH2 | |
| SCHEMBL4349886 | 0.82 | ABL1 (0.60) | KIF11RXRARXRBRXRGESR1 | |
| SCHEMBL29319988 | 0.81 | RXRA (0.48) | KIF11RXRARXRBRXRGABL1 | |
| SCHEMBL322980 | 0.81 | KIF11 (0.63) | KIF11ESR1ABL1ABCB1BCR | |
| SCHEMBL26549571 | 0.81 | ESR1 (0.60) | KIF11RXRARXRBRXRGESR1 | |
| SCHEMBL9482063 | 0.80 | RXRA (0.54) | KIF11RXRARXRBRXRG | |
| SCHEMBL28222642 | 0.79 | KIF11 (0.70) | KIF11RXRARXRBRXRGDGAT1 | |
| SCHEMBL19331992 | 0.79 | RXRA (0.57) | KIF11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | claimed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | claimed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| CN-105693634-B | Compound and application thereof | 清华大学 | 2018-12-11 | — | — | CN | disclosed |
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | BROOKS DAWN A | 2007-11-29 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | disclosed |
| EP-1392637-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100813-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | KIF11 1340/4885RXRA 917/4885RXRB 919/4885 |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | NCOA4, PPARG, PPARA | KIF11 3653/4885RXRA 40/4885RXRB 36/4885 |
| US-20070276138-A1 | Modulators of peroxisome proliferator activated receptors | PPARG, NCOA4, PPARA | KIF11 3569/4885RXRA 31/4885RXRB 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.